Abbott Laboratories $ABT Shares Sold by Capstone Financial Advisors Inc.

Capstone Financial Advisors Inc. lessened its position in shares of Abbott Laboratories (NYSE:ABT) by 11.8% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 3,312 shares of the healthcare product maker’s stock after selling 441 shares during the quarter. Capstone Financial Advisors Inc.’s holdings in Abbott Laboratories were worth $450,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the company. Advisors Capital Management LLC grew its position in shares of Abbott Laboratories by 1.4% during the 2nd quarter. Advisors Capital Management LLC now owns 201,099 shares of the healthcare product maker’s stock valued at $27,352,000 after acquiring an additional 2,697 shares during the period. Grandfield & Dodd LLC boosted its position in Abbott Laboratories by 3.4% during the second quarter. Grandfield & Dodd LLC now owns 14,649 shares of the healthcare product maker’s stock worth $1,993,000 after purchasing an additional 486 shares in the last quarter. Burling Wealth Partners LLC grew its holdings in Abbott Laboratories by 1.5% in the second quarter. Burling Wealth Partners LLC now owns 85,348 shares of the healthcare product maker’s stock valued at $11,608,000 after purchasing an additional 1,249 shares during the period. Oak Harvest Investment Services raised its stake in shares of Abbott Laboratories by 34.4% during the 2nd quarter. Oak Harvest Investment Services now owns 86,723 shares of the healthcare product maker’s stock worth $11,795,000 after buying an additional 22,197 shares during the period. Finally, Nixon Peabody Trust Co. lifted its position in shares of Abbott Laboratories by 2.4% during the 2nd quarter. Nixon Peabody Trust Co. now owns 19,462 shares of the healthcare product maker’s stock valued at $2,647,000 after buying an additional 452 shares in the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories Stock Up 0.3%

Shares of NYSE ABT opened at $129.16 on Friday. The company has a current ratio of 1.82, a quick ratio of 1.30 and a debt-to-equity ratio of 0.25. The company has a 50-day moving average of $130.42 and a 200 day moving average of $131.34. Abbott Laboratories has a 12-month low of $110.86 and a 12-month high of $141.23. The stock has a market cap of $224.59 billion, a PE ratio of 16.19, a P/E/G ratio of 2.36 and a beta of 0.68.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.30. Abbott Laboratories had a return on equity of 17.78% and a net margin of 31.88%.The business had revenue of $11.37 billion during the quarter, compared to analyst estimates of $11.40 billion. During the same period in the prior year, the business earned $1.21 earnings per share. The business’s revenue was up 6.9% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. As a group, sell-side analysts predict that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, November 17th. Stockholders of record on Wednesday, October 15th will be issued a dividend of $0.59 per share. This represents a $2.36 annualized dividend and a dividend yield of 1.8%. The ex-dividend date is Wednesday, October 15th. Abbott Laboratories’s payout ratio is currently 29.57%.

Analyst Ratings Changes

Several equities research analysts recently commented on the stock. Wells Fargo & Company boosted their price target on shares of Abbott Laboratories from $142.00 to $146.00 and gave the stock an “overweight” rating in a report on Thursday, October 16th. Evercore ISI cut their target price on shares of Abbott Laboratories from $144.00 to $142.00 and set an “outperform” rating for the company in a research note on Wednesday, October 15th. Sanford C. Bernstein upped their price target on shares of Abbott Laboratories from $145.00 to $150.00 and gave the stock an “outperform” rating in a research report on Thursday, October 16th. Mizuho lifted their price objective on Abbott Laboratories from $135.00 to $140.00 and gave the stock a “neutral” rating in a report on Tuesday, October 14th. Finally, Royal Bank Of Canada reissued an “outperform” rating and set a $147.00 target price on shares of Abbott Laboratories in a report on Thursday, October 16th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and an average price target of $147.00.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.